Bioretec Ltd – Managers’ transactions – Stephen Industries Inc Oy

 Bioretec Ltd      Managers’ transactions 10 June 2025 at 4.30 p.m. EET

Bioretec Oy - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Stephen Industries Inc Oy

Position: Closely associated person

(X) Legal person  (1):Person Discharging Managerial Responsibilities In Issuer

Name: Kustaa Poutiainen

Position: Member of the Board

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 111620/4/4

 

____________________________________________

Transaction date: 2025-06-10

Outside a trading venue

Instrument type: SHARE

ISIN: FI4000480454

Nature of transaction: SUBSCRIPTION

 

 

Transaction details

(1): Volume: 639092 Unit price: 1.5 EUR

 

Aggregated transactions (1):

Volume: 639092 Volume weighted average price: 1.5 EUR

 

Further enquiries

Sarah van Hellenberg Hubar-Fisher, Interim CEO, +31 6 1544 8736

Johanna Salko, CFO, +358 40 754 8172

 

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is commercializing and developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite - a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and enhance bone remodeling, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential make implant removal operations redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable over USD 10 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com